Exosomes are small extracellular vesicles (30-150 nm) naturally secreted by most cell types, carrying protein, lipid, and nucleic acid cargo. They represent the body's own intercellular communication system and have evolved to efficiently deliver payloads between cells — including across biological barriers like the blood-brain barrier (BBB). For neurodevelopmental epilepsies (NDEs), exosome-based delivery offers a biologics approach that combines favorable safety properties with inherent CNS tropism[1].
Unlike lipid nanoparticles (LNPs), which are synthetically assembled, exosomes are biological particles with native membrane proteins and lipid compositions that can facilitate cell-type-specific targeting. This makes them attractive for delivering gene therapies to specific neuronal populations — particularly the GABAergic interneurons that are the primary therapeutic target in Dravet syndrome (via SCN1A).
Exosomes are generated through the endosomal pathway:
Key exosome components:
Several cell-derived exosomes exhibit natural tropism for the brain:
The combination of small size (40-120 nm), flexible lipid composition, and specific surface protein signatures allows exosomes to navigate the neurovascular unit more effectively than larger particles[2].
| Advantage | Description | NDE Relevance |
|---|---|---|
| BBB crossing | Natural transcytosis capability, especially MSC-derived | Critical for systemically administered NDE therapies |
| Cell-type specificity | Surface engineering can target specific neuronal subtypes | Enable targeting of GABAergic interneurons for SCN1A |
| Immunogenicity | Low pre-existing immunity, even with repeat dosing | Safe for pediatric NDE applications |
| Cargo versatility | Carries mRNA, ASO, siRNA, CRISPR, proteins | Versatile across NDE therapeutic modalities |
| Biologic safety | No viral genes, non-replicating, biodegradable | Safer than AAV for pediatric CNS delivery |
| Neuronal uptake | Naturally fusogenic with neuronal membranes | Efficient delivery to target neurons |
Exosome surface proteins can be engineered to enhance targeting:
Ligand Display: Express targeting ligands (antibodies, peptides, aptamers) on the exosome surface using engineered fusion proteins:
Glycosylation targeting: Specific sugar residues on exosome surface proteins can bind brain endothelial lectins, facilitating transcytosis
Brain-targeting peptide display: Rabies virus-derived peptides (e.g., RVG fragment) displayed on exosome surface for neuronal targeting via acetylcholine receptor binding
| Method | Description | Efficiency |
|---|---|---|
| Electroporation | Electric field pulses create pores in exosome membrane | Good for nucleic acids, may damage membranes |
| Sonication | Acoustic cavitation temporarily permeabilizes membrane | Moderate efficiency |
| Extrusion | Force cargo through exosome membrane | Higher efficiency, may damage exosome |
| Lipid fusion | Fuse liposomes loaded with cargo to exosomes | Preserves integrity |
| Endogenous loading | Engineer donor cells to load cargo into exosomes | Most physiological |
| Click chemistry | Covalent attachment of cargo to exosome surface | Enables precise targeting |
For SCN1A/Dravet therapy, exosomes must preferentially target GABAergic interneurons:
For Angelman syndrome and UBE3A-targeting therapies, exosome delivery of GTX-102 or similar ASOs could improve CNS penetration and reduce off-target peripheral effects[3].
Potential advantages over naked ASO delivery:
Exosome-encapsulated SCN1A mRNA could provide transient expression of functional Nav1.1 channels in inhibitory interneurons, potentially bridging the gap before developmental damage becomes irreversible.
Exosomes can deliver CRISPR-Cas9 systems (mRNA + gRNA) for gene editing in CNS neurons. This is particularly relevant for:
| Company/Group | Approach | Status |
|---|---|---|
| Caperna (Roche) | Engineered exosomes for CNS delivery | Preclinical |
| Evox Therapeutics | Engineered exosome platform | Preclinical |
| Codiak BioSciences | exoSTING and exoIL-12 programs | Clinical (oncology) |
| PureTech | Glyph technology (exosome targeting) | Research |
| Academic consortia | MSC exosome GMP production | GMP-grade available |
Clinical-grade exosome manufacturing follows a standardized pathway:
Current GMP exosome costs are high (~$10,000-50,000 per patient dose) but expected to decrease with improved manufacturing efficiency.
| Factor | Exosomes | LNP | AAV |
|---|---|---|---|
| BBB penetration | Moderate-high (engineered) | Low-moderate | Moderate |
| Cell-type specificity | High (surface engineering) | Moderate | Serotype-dependent |
| Immunogenicity | Very low | Low | Moderate-high |
| Manufacturing scale | Challenging | Scalable | Complex |
| Cargo capacity | Large (proteins, mRNA, CRISPR) | Large (mRNA, CRISPR) | Limited (~4.7kb) |
| Duration | Transient | Transient | Long-term |
| Redosing | Fully repeatable | Fully repeatable | Limited |
| Cost | High | Moderate | Very high |
| Clinical stage | Early (mostly preclinical) | Growing (CNS trials) | Mature (multiple approved) |
Herrmann IK, et al. Extracellular vesicles as drug delivery systems for the brain. Advanced Drug Delivery Reviews. 2022. ↩︎
Matsumoto J, et al. Engineered exosomes for targeted delivery of therapeutics to the brain. Nature Biomedical Engineering. 2020. ↩︎
Mohammad S, et al. Exosome-based delivery of ASOs for neurodevelopmental disorders. Cell Reports Medicine. 2023. ↩︎
Strempfl KE, et al. Exosome-mediated delivery of CRISPR-Cas9 for neurological disease. Molecular Therapy. 2024. ↩︎